Mardepodect

Drug Profile

Mardepodect

Alternative Names: MP-10; PF-02545920; PF-2545920

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antipsychotics; Pyrazoles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 02 May 2017 Discontinued - Phase-I for Huntington's disease (In volunteers) in Sweden (PO) (Pfizer pipeline, May 2017)
  • 02 May 2017 Discontinued - Phase-II for Huntington's disease (Early-stage disease) in France (PO) (Pfizer pipeline, May 2017)
  • 02 May 2017 Discontinued - Phase-II for Huntington's disease in Canada, United Kingdom, Germany, Poland, USA (PO) (Pfizer pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top